Once the bedrock of pharmaceutical profits, the lucrative market for heart disease treatments is rapidly eroding, leaving drugmakers and Wall Street investors scrambling. Despite heart disease remaining humanity’s leading cause of death, the industry that once thrived on its prevalence is now facing unprecedented challenges in monetizing this critical health area, signaling a significant shift in the financial landscape of Big Pharma.
Adapted from: WSJ.com: Markets
